



**Physician Assistant Policy Committee minutes
May 9, 2017**

The meeting was called to order at approximately 1:47 p.m. on Tuesday May 9, 2017.

Committee members present: Irina Petty, PA-C; Megan Keller, R.Ph.; Megan Marchal, R.Ph.; Kindra Engle, D.O.; Robert Zaayer, PA-C; Nancy Ivansek, PA-C; Curtis Gingrich, M.D., and Anita Steinbergh, D.O.

Staff members present: Sallie Debolt, and Cathy Hacker.

Guest: Mandi Grandjean, OAPA.

I. Review of the January 10, 2017 minutes:

Dr. Gingrich moved to approve the minutes. Ms. Ivansek seconded the motion. Dr. Steinbergh abstained. All other members voted aye. The motion carried.

Ms. Ivansek noted that the formulary organization needs to be easy for the pharmacists as well. The committee agreed that this will be a difficult task to make this workable for all involved.

II. Formulary Review

The committee reviewed the following new drugs to the market, as listed in Facts and Comparison, and recommended the following categories for these medications.

- Lartruvo Antineoplastic Agent was added as a may not as all antineoplastic agents are currently in the CTP may not prescribe category.
- Zinplava was added as a miscellaneous GI drugs under the physician initiated/consultation.
- Intrarosa was tabled as is not yet available on the market.
-
- Eucrisa was added in the Anti-inflammatory section as a CTP may prescribe.
-
- Spinraza it was noted that this medication is similar to Xondys and that is already in the miscellaneous Neurologic Agents as a CTP may not prescribe.
-
- Trulance was added as a miscellaneous GI drugs under as a CTP may prescribe

Dr. Steinbergh moved to approve these changes to the formulary. Ms. Ivansek seconded the motion. All members voted aye. The motion carried.

The committee then reviewed the requests from Dr. Jeremy Groll to reclassify the following medications.

He requests to move **Femara** from the PI category to CTP may prescribe category as it is commonly used for ovulation induction. The committee decided to maintain it as Physician Initiated as PA's are not able to prescribe antineoplastic agents and the proposed use is off-label.

- He requests to move **Cabergoline** from the CTP may not prescribe category to CTP may prescribe category as it is commonly used for hyperprolactinemia. The committee moved this to the PI category as it is used in all types of practice specialties.
- He requests to move **Ganirelix** from the CTP may not prescribe category to PI category as it is commonly used for invitrofertilization protocols. This was moved to the PI category.
- He requests to move **Cetrorelix** from the CTP may not prescribe category to PI category as it is commonly used for invitrofertilization protocols. This was moved to the PI category.
- He requests to move **Somatropin** from the CTP may not prescribe category to PI category as it is commonly used for invitrofertilization protocols. The committee left this in the CTP may not prescribe as this request is for off label use.
- He requests to move **Leuprolide** from the CTP may not prescribe category to PI category as it is commonly used for invitrofertilization protocols. The committee left this in the CTP may not prescribe as this request is for off label use.

The committee referred the buprenorphine conversation to the PA/Scope of practice committee for their input.

Dr. Steinbergh moved to approve the above changes to the formulary. Ms. Keller seconded the motion. All members voted aye. The motion carried.

III. Rules review

The committee reviewed proposed rules 4731-11-01, 4731-11-02 and 4731-11-13, which are proposed as applicable to prescribing for acute pain. No comments were made.

The committee also reviewed proposed rules 4731-28-02, 4731-28-03, 4731-28-04 and 4731-28-05, which are proposed to establish a confidential monitoring program for all licenses. The committee had no comments.

IV. New business

No new business was discussed.

The Physician Assistant Policy Committee meeting was adjourned by Mr. Zaayer at approximately 3:22 p.m. on Tuesday, May 9, 2017.

I hereby attest that these are the true and accurate minutes of the Physician Assistant Policy Committee of the State Medical Board of Ohio, meeting on May 9, 2017.

Robert Zaayer, PA-C, Chair, PAPC